GlobeNewswire: Ovid Therapeutics Inc. Contains the last 10 of 164 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:12:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/08/2843091/0/en/Ovid-Therapeutics-Reports-Business-Updates-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results2024-03-08T13:00:00Z<![CDATA[NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/02/28/2836903/0/en/Ovid-Therapeutics-to-Present-at-the-TD-Cowen-44th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference2024-02-28T13:00:00Z<![CDATA[NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a panel titled “Orphan Epilepsies” at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts.]]>https://www.globenewswire.com/news-release/2024/02/06/2824229/0/en/Ovid-Therapeutics-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-02-06T13:00:00Z<![CDATA[NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.]]>https://www.globenewswire.com/news-release/2023/12/01/2789250/0/en/Ovid-Therapeutics-to-Present-Five-Abstracts-Supporting-its-Epilepsy-Programs-at-the-77th-American-Epilepsy-Society-Annual-Meeting-2023.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)2023-12-01T12:30:00Z<![CDATA[NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.]]>https://www.globenewswire.com/news-release/2023/11/03/2773136/0/en/Ovid-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Corporate-Updates.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates2023-11-03T12:00:00Z<![CDATA[NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.]]>https://www.globenewswire.com/news-release/2023/10/18/2762278/0/en/Ovid-Therapeutics-and-Ligand-Pharmaceuticals-Enter-into-a-30-Million-Agreement-for-a-13-Interest-in-Soticlestat-Royalties-and-Milestones-Extending-Ovid-s-Cash-Runway-into-2026.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 20262023-10-18T12:00:00Z<![CDATA[NEW YORK and SAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of soticlestat. In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.]]>https://www.globenewswire.com/news-release/2023/10/10/2757419/0/en/Ovid-Therapeutics-to-Present-at-the-Jefferies-Biotech-CNS-Neuro-Summit.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit2023-10-10T12:00:00Z<![CDATA[NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a presentation at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 3:30 p.m. ET in New York.]]>https://www.globenewswire.com/news-release/2023/09/26/2749357/0/en/Ovid-Therapeutics-to-Host-Investor-Event-R-D-Day-on-Monday-October-2-2023.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 20232023-09-26T11:30:00Z<![CDATA[NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&D) Day investor event on Monday, October 2, 2023. The event will take place at the Company’s headquarters in New York’s Hudson Yards from 12:00 pm - 2:30 pm and will be webcast simultaneously.]]>https://www.globenewswire.com/news-release/2023/09/20/2746343/0/en/Ovid-Therapeutics-to-Present-at-the-2023-Cantor-Fitzgerald-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference2023-09-20T11:30:00Z<![CDATA[NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York.]]>https://www.globenewswire.com/news-release/2023/08/30/2734267/0/en/Ovid-Therapeutics-to-Participate-in-Upcoming-September-Investor-Conferences.html?f=22&fvtc=4&fvtv=30715Ovid Therapeutics to Participate in Upcoming September Investor Conferences2023-08-30T12:00:00Z<![CDATA[NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in two upcoming investor conferences.]]>